Kind Code A1
Wang; Xiaohuai ; et al. May 27, 2010
METHOD OF USE OF PORPHYRINS IN PREPARING A MEDICAMENT FOR SONODYNAMIC THERAPY AND A METHOD OF SONODYNAMIC THERAPY USING PORPHYRINS
Abstract
The invention provides method of use of a porphyrin compound as shown below in preparing a medicament for sonodynamic therapy, and a method of sonodynamic therapy using a porphyrin compound. Said therapy comprises administering a porphyrin compound to a patient and applying sonic wave to the patient, ##STR00001## ##STR00002## wherein each symbol has the meaning as defined in the description.
Inventors: Wang; Xiaohuai; (Guangzhou, CN) ; Su; Jiangan; (Shanghai, CN) ; Li; Qing; (Guangzhou, CN) ; Zhao; Guanglian; (Shanghai, CN) ; Luo; Yifan; (Guangdong Province, CN) ; Yu; Bo; (Shanghai, CN)
Assignee Name and Adress: Science Group Pty. Ltd.
Victoria
AU
Serial No.: 323174
Series Code: 12
Filed: November 25, 2008
[0124]III A Clinical Case
[0125]A patient, female, 69 years old, with right breast carcinoma. 10 months after surgery and chemotherapy, a tumor metastasis was detected in liver as shows by Computed Tomography-Positron Emission Tomography (CT-PET) on Nov. 9, 2007 (see FIG. 5). The lysine form of tin chlorophyllin as indicated in the above animal test B was dissolved in 0.1 mol/L phosphate buffer (pH 7.4) and given to the patient through lingual absorption every day for 2 days. Total dose of the lysine form of tin chlorophyllin was 60 mg. After 24 h, the red light light-emitting diode (LED) was irradiated to the body surface followed by local ultrasound irradiating of the tumour area at the intensities of 2.0 W/cm.sup.2 for 20 minutes in a water bathtub every day for 3 days. One week later, the treatment was repeated. After 3 cycles of SDT treatment with the lysine form of tin chlorophyllin, CT-PET scan on Jan. 10, 2008 showed the tumor shrank and the tumor metabolic activity was inhibited (see FIG. 5). Her symptom was much improved and Blood Routine and chemistry tests showed normal result.
Source
EEC BIO-TECH (GUANGZHOU) CO., LTD (EEC Biotech), a wholly-owned subsidiary of SCIENCE GROUP PTY LTD (SG) of Australia, is a limited liability company engaged in the professional research, development and medical application of modern bio-technology, particularly in the treatment of cancer.
EEC Biotech’s Head Office is located in Guangzhou, Guangdong Province, China. On the strength of the holding company SG’s rapidly expanding global information and business network, coupled with EEC Biotech’s good relations with China’s various research and development organisations, EEC Biotech is able to quickly penetrate and develop China’s and even the global medical bio-tech market.
EEC Biotech aims to be part of the cutting-edge in the fight against cancer by funding and developing break-through medical innovations through to creatively working on patient treatment delivery.
The Company’s primary focus has been on the development of Sono-Photo Dynamic Therapy (SPDT) technology, which is a new generation of anti-tumour technology developed from Photo-Dynamic Therapy (PDT).
PDT has been widely used as an anti-tumour treatment for over 100 years. It is approved for use in many countries. SPDT uses the same theory as PDT but is more advanced and effective as it contains both sound and light activation in the process. SPDT uses a chlorophyll sensitizer, which is activated by both sound and light. SPDT is a safe, non-invasive, non-toxic treatment option that allows greater flexibility in treatment and can enhance other conventional therapies such as chemotherapy and radiation.
The Company has developed a first class leadership team dealing with research and development, promotion and marketing. At the same time, it has also sought wide-ranging cooperation with various universities and professional research institutions in Australia, America and China, giving rise to an organisation with strong multi-disciplined R & D, covering areas such as bio-technology, medicine, chemistry, physics, electronics and information technology.
The Company currently has three professional clinical R & D centres in China with one anti-cancer Research Institute approved by the Chinese Government (Shaanxi EEC Cancer Research Institute). Overseas, it also has three cooperative clinical organisations in Australia, America and the United Kingdom. It is a corporate member of the Guangzhou Anti-Cancer Association, the Shaanxi Anti-Cancer Association and the American Society of Clinical Oncology.
EEC Biotech possesses several globally-leading patented technologies on cancer treatment, both within and without China.
EEC BIO-TECH (GUANGZHOU) CO., LTD (EEC Biotech), a wholly-owned subsidiary of SCIENCE GROUP PTY LTD (SG) of Australia, is a limited liability company engaged in the professional research, development and medical application of modern bio-technology, particularly in the treatment of cancer.
EEC Biotech’s Head Office is located in Guangzhou, Guangdong Province, China. On the strength of the holding company SG’s rapidly expanding global information and business network, coupled with EEC Biotech’s good relations with China’s various research and development organisations, EEC Biotech is able to quickly penetrate and develop China’s and even the global medical bio-tech market.
EEC Biotech aims to be part of the cutting-edge in the fight against cancer by funding and developing break-through medical innovations through to creatively working on patient treatment delivery.
The Company’s primary focus has been on the development of Sono-Photo Dynamic Therapy (SPDT) technology, which is a new generation of anti-tumour technology developed from Photo-Dynamic Therapy (PDT).
PDT has been widely used as an anti-tumour treatment for over 100 years. It is approved for use in many countries. SPDT uses the same theory as PDT but is more advanced and effective as it contains both sound and light activation in the process. SPDT uses a chlorophyll sensitizer, which is activated by both sound and light. SPDT is a safe, non-invasive, non-toxic treatment option that allows greater flexibility in treatment and can enhance other conventional therapies such as chemotherapy and radiation.
The Company has developed a first class leadership team dealing with research and development, promotion and marketing. At the same time, it has also sought wide-ranging cooperation with various universities and professional research institutions in Australia, America and China, giving rise to an organisation with strong multi-disciplined R & D, covering areas such as bio-technology, medicine, chemistry, physics, electronics and information technology.
The Company currently has three professional clinical R & D centres in China with one anti-cancer Research Institute approved by the Chinese Government (Shaanxi EEC Cancer Research Institute). Overseas, it also has three cooperative clinical organisations in Australia, America and the United Kingdom. It is a corporate member of the Guangzhou Anti-Cancer Association, the Shaanxi Anti-Cancer Association and the American Society of Clinical Oncology.
EEC Biotech possesses several globally-leading patented technologies on cancer treatment, both within and without China.
Source
